CIPLA1,374.00

Cipla Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.11L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)366.22380.69412.18412.18
Receivable Days (DSO)67.5672.9672.8472.84
Payable Days (DPO)172.97191.45201.81205.77
Cash Conversion Cycle (days)260.81262.20283.21279.25
Working Capital Turnover1.821.551.641.65
Asset Turnover0.790.740.660.66
Cash Conversion (CFO/Net Income)1.000.951.021.02
CFO/EBITDA0.660.700.670.67
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 146%.